Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing Article Swipe
Nobuki Furubayashi
,
Manabu Mochida
,
Aki Kijima
,
Yo Fujimoto
,
Motonobu Nakamura
,
Takahito Negishi
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.21873/invivo.13903
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.21873/invivo.13903
The efficacy and safety of avelumab maintenance therapy was not significantly influenced by age, PS, or infusion timing, and PFS ≥6 months could be a surrogate marker for OS.
Related Topics
Concepts
Avelumab
Urothelial carcinoma
Medicine
Oncology
Internal medicine
Carcinoma
Performance status
Overall survival
Immunotherapy
Cancer
Bladder cancer
Pembrolizumab
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.21873/invivo.13903
- https://iv.iiarjournals.org/content/invivo/39/2/976.full.pdf
- OA Status
- diamond
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4407967193
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4407967193Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21873/invivo.13903Digital Object Identifier
- Title
-
Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and TimingWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-02-26Full publication date if available
- Authors
-
Nobuki Furubayashi, Manabu Mochida, Aki Kijima, Yo Fujimoto, Motonobu Nakamura, Takahito NegishiList of authors in order
- Landing page
-
https://doi.org/10.21873/invivo.13903Publisher landing page
- PDF URL
-
https://iv.iiarjournals.org/content/invivo/39/2/976.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://iv.iiarjournals.org/content/invivo/39/2/976.full.pdfDirect OA link when available
- Concepts
-
Avelumab, Urothelial carcinoma, Medicine, Oncology, Internal medicine, Carcinoma, Performance status, Overall survival, Immunotherapy, Cancer, Bladder cancer, PembrolizumabTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4407967193 |
|---|---|
| doi | https://doi.org/10.21873/invivo.13903 |
| ids.doi | https://doi.org/10.21873/invivo.13903 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40010984 |
| ids.openalex | https://openalex.org/W4407967193 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000368 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Aged |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D008297 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Male |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D005260 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Female |
| mesh[4].qualifier_ui | Q000008 |
| mesh[4].descriptor_ui | D061067 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | administration & dosage |
| mesh[4].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[5].qualifier_ui | Q000009 |
| mesh[5].descriptor_ui | D061067 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | adverse effects |
| mesh[5].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[6].qualifier_ui | Q000627 |
| mesh[6].descriptor_ui | D061067 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | therapeutic use |
| mesh[6].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D000369 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Aged, 80 and over |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D008875 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Middle Aged |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D016896 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Treatment Outcome |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D012189 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Retrospective Studies |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000367 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Age Factors |
| mesh[12].qualifier_ui | Q000009 |
| mesh[12].descriptor_ui | D000074322 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | adverse effects |
| mesh[12].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[13].qualifier_ui | Q000008 |
| mesh[13].descriptor_ui | D000074322 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | administration & dosage |
| mesh[13].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[14].qualifier_ui | Q000627 |
| mesh[14].descriptor_ui | D000074322 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | therapeutic use |
| mesh[14].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D009367 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Neoplasm Staging |
| mesh[16].qualifier_ui | Q000188 |
| mesh[16].descriptor_ui | D014571 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | drug therapy |
| mesh[16].descriptor_name | Urologic Neoplasms |
| mesh[17].qualifier_ui | Q000473 |
| mesh[17].descriptor_ui | D014571 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | pathology |
| mesh[17].descriptor_name | Urologic Neoplasms |
| mesh[18].qualifier_ui | Q000401 |
| mesh[18].descriptor_ui | D014571 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | mortality |
| mesh[18].descriptor_name | Urologic Neoplasms |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D006801 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Humans |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D008297 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Male |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D005260 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Female |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D000368 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Aged |
| mesh[23].qualifier_ui | Q000627 |
| mesh[23].descriptor_ui | D061067 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | therapeutic use |
| mesh[23].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[24].qualifier_ui | Q000008 |
| mesh[24].descriptor_ui | D061067 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | administration & dosage |
| mesh[24].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[25].qualifier_ui | Q000009 |
| mesh[25].descriptor_ui | D061067 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | adverse effects |
| mesh[25].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D000369 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Aged, 80 and over |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D008875 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Middle Aged |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D016896 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Treatment Outcome |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D000367 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Age Factors |
| mesh[30].qualifier_ui | Q000188 |
| mesh[30].descriptor_ui | D014571 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | drug therapy |
| mesh[30].descriptor_name | Urologic Neoplasms |
| mesh[31].qualifier_ui | Q000473 |
| mesh[31].descriptor_ui | D014571 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | pathology |
| mesh[31].descriptor_name | Urologic Neoplasms |
| mesh[32].qualifier_ui | Q000401 |
| mesh[32].descriptor_ui | D014571 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | mortality |
| mesh[32].descriptor_name | Urologic Neoplasms |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D009367 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Neoplasm Staging |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D012189 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Retrospective Studies |
| mesh[35].qualifier_ui | Q000473 |
| mesh[35].descriptor_ui | D019459 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | pathology |
| mesh[35].descriptor_name | Urothelium |
| mesh[36].qualifier_ui | Q000187 |
| mesh[36].descriptor_ui | D019459 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | drug effects |
| mesh[36].descriptor_name | Urothelium |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D006801 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Humans |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D008297 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Male |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D005260 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Female |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D000368 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Aged |
| mesh[41].qualifier_ui | Q000627 |
| mesh[41].descriptor_ui | D061067 |
| mesh[41].is_major_topic | True |
| mesh[41].qualifier_name | therapeutic use |
| mesh[41].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[42].qualifier_ui | Q000008 |
| mesh[42].descriptor_ui | D061067 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | administration & dosage |
| mesh[42].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[43].qualifier_ui | Q000009 |
| mesh[43].descriptor_ui | D061067 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | adverse effects |
| mesh[43].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D000369 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Aged, 80 and over |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D008875 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Middle Aged |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D016896 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Treatment Outcome |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D000367 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | Age Factors |
| mesh[48].qualifier_ui | Q000188 |
| mesh[48].descriptor_ui | D014571 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | drug therapy |
| mesh[48].descriptor_name | Urologic Neoplasms |
| mesh[49].qualifier_ui | Q000473 |
| mesh[49].descriptor_ui | D014571 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | pathology |
| mesh[49].descriptor_name | Urologic Neoplasms |
| type | article |
| title | Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing |
| biblio.issue | 2 |
| biblio.volume | 39 |
| biblio.last_page | 987 |
| biblio.first_page | 976 |
| topics[0].id | https://openalex.org/T10458 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9962000250816345 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Bladder and Urothelial Cancer Treatments |
| topics[1].id | https://openalex.org/T12695 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9448000192642212 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2746 |
| topics[1].subfield.display_name | Surgery |
| topics[1].display_name | Urinary and Genital Oncology Studies |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777381376 |
| concepts[0].level | 5 |
| concepts[0].score | 0.8375346064567566 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q21083261 |
| concepts[0].display_name | Avelumab |
| concepts[1].id | https://openalex.org/C3019882237 |
| concepts[1].level | 4 |
| concepts[1].score | 0.7350306510925293 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q2501186 |
| concepts[1].display_name | Urothelial carcinoma |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.5028395056724548 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C143998085 |
| concepts[3].level | 1 |
| concepts[3].score | 0.4938143193721771 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[3].display_name | Oncology |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.4362376034259796 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C2777546739 |
| concepts[5].level | 2 |
| concepts[5].score | 0.433685839176178 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q33525 |
| concepts[5].display_name | Carcinoma |
| concepts[6].id | https://openalex.org/C2776907518 |
| concepts[6].level | 3 |
| concepts[6].score | 0.4281967580318451 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1734165 |
| concepts[6].display_name | Performance status |
| concepts[7].id | https://openalex.org/C3019894029 |
| concepts[7].level | 2 |
| concepts[7].score | 0.23672226071357727 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q332823 |
| concepts[7].display_name | Overall survival |
| concepts[8].id | https://openalex.org/C2777701055 |
| concepts[8].level | 3 |
| concepts[8].score | 0.17744740843772888 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[8].display_name | Immunotherapy |
| concepts[9].id | https://openalex.org/C121608353 |
| concepts[9].level | 2 |
| concepts[9].score | 0.13060212135314941 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[9].display_name | Cancer |
| concepts[10].id | https://openalex.org/C2780352672 |
| concepts[10].level | 3 |
| concepts[10].score | 0.12393739819526672 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q504775 |
| concepts[10].display_name | Bladder cancer |
| concepts[11].id | https://openalex.org/C2780057760 |
| concepts[11].level | 4 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q13896859 |
| concepts[11].display_name | Pembrolizumab |
| keywords[0].id | https://openalex.org/keywords/avelumab |
| keywords[0].score | 0.8375346064567566 |
| keywords[0].display_name | Avelumab |
| keywords[1].id | https://openalex.org/keywords/urothelial-carcinoma |
| keywords[1].score | 0.7350306510925293 |
| keywords[1].display_name | Urothelial carcinoma |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.5028395056724548 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/oncology |
| keywords[3].score | 0.4938143193721771 |
| keywords[3].display_name | Oncology |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.4362376034259796 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/carcinoma |
| keywords[5].score | 0.433685839176178 |
| keywords[5].display_name | Carcinoma |
| keywords[6].id | https://openalex.org/keywords/performance-status |
| keywords[6].score | 0.4281967580318451 |
| keywords[6].display_name | Performance status |
| keywords[7].id | https://openalex.org/keywords/overall-survival |
| keywords[7].score | 0.23672226071357727 |
| keywords[7].display_name | Overall survival |
| keywords[8].id | https://openalex.org/keywords/immunotherapy |
| keywords[8].score | 0.17744740843772888 |
| keywords[8].display_name | Immunotherapy |
| keywords[9].id | https://openalex.org/keywords/cancer |
| keywords[9].score | 0.13060212135314941 |
| keywords[9].display_name | Cancer |
| keywords[10].id | https://openalex.org/keywords/bladder-cancer |
| keywords[10].score | 0.12393739819526672 |
| keywords[10].display_name | Bladder cancer |
| language | en |
| locations[0].id | doi:10.21873/invivo.13903 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S115443242 |
| locations[0].source.issn | 0258-851X, 1791-7549 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 0258-851X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | In Vivo |
| locations[0].source.host_organization | https://openalex.org/P4322764940 |
| locations[0].source.host_organization_name | Stanford University Highwire Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4322764940 |
| locations[0].license | |
| locations[0].pdf_url | https://iv.iiarjournals.org/content/invivo/39/2/976.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | In Vivo |
| locations[0].landing_page_url | https://doi.org/10.21873/invivo.13903 |
| locations[1].id | pmid:40010984 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | In vivo (Athens, Greece) |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40010984 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:11884485 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | In Vivo |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11884485 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5071222216 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9159-493X |
| authorships[0].author.display_name | Nobuki Furubayashi |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210093709 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I4210093709 |
| authorships[0].institutions[0].ror | https://ror.org/00mce9b34 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210093709, https://openalex.org/I4210137409 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | National Hospital Organization Kyushu Cancer Center |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | NOBUKI FURUBAYASHI |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[1].author.id | https://openalex.org/A5001206415 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Manabu Mochida |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210093709 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I4210093709 |
| authorships[1].institutions[0].ror | https://ror.org/00mce9b34 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210093709, https://openalex.org/I4210137409 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | National Hospital Organization Kyushu Cancer Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | MANABU MOCHIDA |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[2].author.id | https://openalex.org/A5069815128 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Aki Kijima |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210093709 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I4210093709 |
| authorships[2].institutions[0].ror | https://ror.org/00mce9b34 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210093709, https://openalex.org/I4210137409 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | National Hospital Organization Kyushu Cancer Center |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | ATSUHIRO KIJIMA |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[3].author.id | https://openalex.org/A5112676596 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Yo Fujimoto |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210093709 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I4210093709 |
| authorships[3].institutions[0].ror | https://ror.org/00mce9b34 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210093709, https://openalex.org/I4210137409 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | National Hospital Organization Kyushu Cancer Center |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | YUSHI FUJIMOTO |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[4].author.id | https://openalex.org/A5102955473 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-3038-1361 |
| authorships[4].author.display_name | Motonobu Nakamura |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210093709 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I4210093709 |
| authorships[4].institutions[0].ror | https://ror.org/00mce9b34 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210093709, https://openalex.org/I4210137409 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | National Hospital Organization Kyushu Cancer Center |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | MOTONOBU NAKAMURA |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[5].author.id | https://openalex.org/A5012284662 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-6645-8829 |
| authorships[5].author.display_name | Takahito Negishi |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210093709 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I4210093709 |
| authorships[5].institutions[0].ror | https://ror.org/00mce9b34 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210093709, https://openalex.org/I4210137409 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | National Hospital Organization Kyushu Cancer Center |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | TAKAHITO NEGISHI |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://iv.iiarjournals.org/content/invivo/39/2/976.full.pdf |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10458 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9962000250816345 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Bladder and Urothelial Cancer Treatments |
| related_works | https://openalex.org/W4238705971, https://openalex.org/W4362539929, https://openalex.org/W2903323937, https://openalex.org/W4220780195, https://openalex.org/W4205638399, https://openalex.org/W4362532809, https://openalex.org/W4200128746, https://openalex.org/W4245854978, https://openalex.org/W4254491264, https://openalex.org/W2058040425 |
| cited_by_count | 0 |
| locations_count | 3 |
| best_oa_location.id | doi:10.21873/invivo.13903 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S115443242 |
| best_oa_location.source.issn | 0258-851X, 1791-7549 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 0258-851X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | In Vivo |
| best_oa_location.source.host_organization | https://openalex.org/P4322764940 |
| best_oa_location.source.host_organization_name | Stanford University Highwire Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4322764940 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://iv.iiarjournals.org/content/invivo/39/2/976.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | In Vivo |
| best_oa_location.landing_page_url | https://doi.org/10.21873/invivo.13903 |
| primary_location.id | doi:10.21873/invivo.13903 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S115443242 |
| primary_location.source.issn | 0258-851X, 1791-7549 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 0258-851X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | In Vivo |
| primary_location.source.host_organization | https://openalex.org/P4322764940 |
| primary_location.source.host_organization_name | Stanford University Highwire Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4322764940 |
| primary_location.license | |
| primary_location.pdf_url | https://iv.iiarjournals.org/content/invivo/39/2/976.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | In Vivo |
| primary_location.landing_page_url | https://doi.org/10.21873/invivo.13903 |
| publication_date | 2025-02-26 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 24 |
| abstract_inverted_index.be | 23 |
| abstract_inverted_index.by | 12 |
| abstract_inverted_index.of | 4 |
| abstract_inverted_index.or | 15 |
| abstract_inverted_index.OS. | 28 |
| abstract_inverted_index.PFS | 19 |
| abstract_inverted_index.PS, | 14 |
| abstract_inverted_index.The | 0 |
| abstract_inverted_index.and | 2, 18 |
| abstract_inverted_index.for | 27 |
| abstract_inverted_index.not | 9 |
| abstract_inverted_index.was | 8 |
| abstract_inverted_index.age, | 13 |
| abstract_inverted_index.≥6 | 20 |
| abstract_inverted_index.could | 22 |
| abstract_inverted_index.marker | 26 |
| abstract_inverted_index.months | 21 |
| abstract_inverted_index.safety | 3 |
| abstract_inverted_index.therapy | 7 |
| abstract_inverted_index.timing, | 17 |
| abstract_inverted_index.avelumab | 5 |
| abstract_inverted_index.efficacy | 1 |
| abstract_inverted_index.infusion | 16 |
| abstract_inverted_index.surrogate | 25 |
| abstract_inverted_index.influenced | 11 |
| abstract_inverted_index.maintenance | 6 |
| abstract_inverted_index.significantly | 10 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.699999988079071 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.09392784 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |